Figure 4
From: Alternative dosing of dual PI3K and MEK inhibition in cancer therapy
Apoptotic response to dual PI3K and MEK inhibition in dual inhibition-sensitive cancer cell lines. (A) Western blot analysis for cleaved PARP (cPARP) in the H3122, H1437, MDA-MB231 and HCT116 lines treated with the PI3K inhibitors ZSTK474 and PI-103, the MEK inhibitor CI-1040, or their combinations for 48 h. (B) Western blot analysis for cleaved PARP in the H3122 cell line treated for 15min with dual inhibition and with the single inhibitor indicated for an additional 48 h, or with the ALK inhibitor TAE684 for 15 min. (C) Western blot analysis for cleaved caspase-3 in the H3122 line with indicated treatments and exposure times.